Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2010

01-12-2010 | Original paper

Pharmacogenetics and pharmacoepigenetics of gemcitabine

Authors: M. Candelaria, E. de la Cruz-Hernández, E. Pérez-Cárdenas, C. Trejo-Becerril, O. Gutiérrez-Hernández, A. Dueñas-González

Published in: Medical Oncology | Issue 4/2010

Login to get access

Abstract

Gemcitabine (2′,2′-difluoro 2′deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug’s therapeutic use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual variation in therapeutic outcome exhibited by gemcitabine.
Literature
1.
Candelaria M, et al. Genetic determinants of cancer drug efficacy and toxicity. Practical considerations and perspectives. Anticancer Drugs. 2005;16:923–33.PubMedCrossRef
2.
Mini E, Nobilli S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7–12.PubMedCrossRef
3.
Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed
4.
Sandler AB, et al. Phase III trial of gemcitabine plus cisplatin vs cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2000;18:122–30.PubMed
5.
von der Maase H, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77.
6.
Gligorov J, et al. Updates on gemcitabine on metastatic breast cancer. Bull Cancer. 2007;94:S90–4.PubMed
7.
Kalykaki A, Hellenic Oncology Research Group, et al. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Anticancer Res. 2008;28(1B):495–500.PubMed
8.
Zucali PA, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–61.PubMedCrossRef
9.
Cetina L, Rivera L, Candelaria-Hernández M, De la Garza J, Dueñas-González A. Chemoradiation for cervical cancer in patients with renal dysfunction. Experience with gemcitabine. Anticancer drugs. 2004;15:761–6.PubMedCrossRef
10.
Candelaria M, Cetina L, de la Garza J, Dueñas-Gonzalez A. Clinical implications of gemcitabine in the treatment of cervical cancer. Eur J Cancer Suppl. 2007;5:37–43.CrossRef
11.
Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990;50:3675–80.PubMed
12.
Huang P, Chubb S, Hertel LW. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110–7.PubMed
13.
Gandhi V, Legha J, Chen F. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphates residues from DNA. Cancer Res. 1996;56:4453–9.PubMed
14.
Heinemann V, Xu YZ, Chubb S. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 1990;38:567–72.PubMed
15.
Heinemann V, Xu YZ, Chubb S. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52:533–9.PubMed
16.
Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res. 2002;112:27–47.PubMed
17.
Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today. 1999;5:216–24.PubMedCrossRef
18.
Hopper-Borge E, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogs and epothilone B. Cancer Res. 2009;69:178–84.PubMedCrossRef
19.
Sheng Z, et al. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003;63:351–8.CrossRef
20.
21.
Abdulla P, Coe IR. Characterization and functional analysis of the promoter for the human equilibrative nucleoside transport gene, hENT1. Nucleosides Nucleotides Nucleic Acids. 2007;26:99–110.PubMedCrossRef
22.
Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183–201.PubMedCrossRef
23.
Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun. 2001;280:951–9.PubMedCrossRef
24.
Zhang J, et al. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 2007;26:85–110.PubMedCrossRef
25.
Griffiths M, et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (EI) equilibrative nucleoside transporter from human placenta. Biochem J. 1997;328:739–43.PubMed
26.
Barnes K, et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res. 2006;99:510–9.PubMedCrossRef
27.
Gati WP, Paerson AR, Larratt LM. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measures by flow cytometry with SAENTA-fluorescein. Blood. 1997;90:346–53.PubMed
28.
Achiwa H, et al. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004;95:753–7.PubMedCrossRef
29.
Choi DS, et al. Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporter 1 (ENT1) gene. Biochem Biophys Res Commun. 2000;277:200–8.PubMedCrossRef
30.
Giovanetti E, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006;5:1387–95.CrossRef
31.
Giovanetti E, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928–35.CrossRef
32.
Spratlin J, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10:6956–61.PubMedCrossRef
33.
Mackey JR, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002;8:110–6.PubMed
34.
Oguri T, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007;256:112–9.PubMedCrossRef
35.
Baldwin SA, Yao SY, Hyde RJ, Foppolo S, Barnes K. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005;280:15880–7.PubMedCrossRef
36.
Ritzel MW, et al. Molecular identification and characterization of novel human and mouse concentrative Na+ nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides. J Biol Chem. 2001;276:2914–27.PubMedCrossRef
37.
Wang J, et al. Na + dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol. 1997;273:F1058–65.PubMed
38.
Wang J, et al. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm Res. 1997;14:1524–32.PubMedCrossRef
39.
Molina-Arcas M, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. 2003;101:2328–34.PubMedCrossRef
40.
Felipe A, et al. Na+ dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. Biochem J. 1998;330:997–1001.PubMed
41.
Lostao MP, et al. Electrogenic uptake of nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett. 2000;481:137–40.PubMedCrossRef
42.
Dragan Y, et al. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology. 2000;32:239–46.PubMedCrossRef
43.
Pastor-Anglada M, et al. Nucleoside transporters and liver cell growth. Biochem Cell Biol. 1998;76:771–7.PubMedCrossRef
44.
Valdes R, et al. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology. 2000;119:623–30.
45.
Mata JF, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5′deoxy-5fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol. 2001;59:1542–8.PubMed
46.
Soler C, et al. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alfa in human B-lymphocytes. J Biol Chem. 1998;273:26939–45.PubMedCrossRef
47.
Farre X, et al. Expression of the nucleoside-derived drug transporters hCNT1, hETN1, hENT2 in gynecologic tumors. Int J Cancer. 2004;112:959–66.PubMedCrossRef
48.
Gloeckner-Hofman K, et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology. 2006;70:238–44.CrossRef
49.
García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cáncer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000–8.PubMed
50.
Cano-Soldado P, et al. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochem Pharmacol. 2008;75:639–48.PubMedCrossRef
51.
Osato DH, et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics. 2003;13:297–301.PubMedCrossRef
52.
Myers SN, et al. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics. 2006;16:315–20.PubMedCrossRef
53.
Gray JH, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol. 2004;65:512–9.PubMedCrossRef
54.
Badagnani I, et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;124:505–12.
55.
Owen RP, Badagnani I, Giacomini KM. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem. 2006;281:26672–82.CrossRef
56.
Errasti-Mugaren E, Cano-Soldado P, Pastor-Anglada M, Casado FJ. Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity. Mol Pharmacol. 2008;73:379–86.CrossRef
57.
Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.PubMedCrossRef
58.
Chen T, Li E. Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol. 2004;60:55–89.PubMedCrossRef
59.
Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine. Biochem Biophys Acta. 2009;1789:45–57.PubMed
60.
61.
Park YJ, Luger K. Structure and function of nucleosome assembly proteins. Biochem Cell Biol. 2006;84:549–58.PubMedCrossRef
62.
Thiriet C, Hayes JJ. Functionally relevant histone-DNA interactions extend beyond the classically defined nucleosome core region. J Biol Chem. 1998;273:21352–8.PubMedCrossRef
63.
Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol. 2001;13:263–73.PubMedCrossRef
64.
Schotta M, Lachner M, Sarma K. A silencing pathway to induce H3–K9 and H4–K20 trimethylation at constitutive heterochromatin. Genes Dev. 2004;18:1251–62.PubMedCrossRef
65.
Cao R, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.PubMedCrossRef
66.
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21–9.PubMed
67.
Zhou X, Ma H. Evolutionary history of histone demethylase families: distinct evolutionary patterns suggest functional divergence. BMC Evol Biol. 2008;8:294.PubMedCrossRef
68.
Kikuchi R, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1 α/β and DNA methylation. Mol Pharmacol. 2006;70:887–96.PubMedCrossRef
69.
Kastrup IB, et al. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol. 2008;80:61–6.PubMed
70.
Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier in inherently methotrexate-resistant human breast cancer cells. J Biol Chem. 2001;276:39990–40000.PubMedCrossRef
71.
Park JY, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:32–9.CrossRef
72.
Shutoh M, et al. DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer. 2005;104:1609–19.PubMedCrossRef
73.
Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg. 2007;137:722–8.PubMedCrossRef
74.
Arce C, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant Doxorubicin cyclophosphamide for locally advanced breast cancer. PloS ONE. 2006;1:e98.PubMedCrossRef
75.
Chottiner EG, et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci. 1991;88:1531–5.PubMedCrossRef
76.
Kroep JR, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 2002;1:371–6.PubMed
77.
Manome Y, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of 1-B-D-arabinofuranosylcytosine in vitro and in vivo. Nat Med. 1996;2:567–73.PubMedCrossRef
78.
Sebastiani V, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492–7.PubMedCrossRef
79.
Galmarini CM, Clarke ML, Jordheim L. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004;4:8.PubMedCrossRef
80.
Lamba J, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007;323:935–45.PubMedCrossRef
81.
Chen E, Johnson EE, Vetter S, Mitchell BS. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest. 1995;95:1660–8.PubMedCrossRef
82.
GE Y, Jensen TL, Matherly LH, Taub JW. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem. 2003;278:49901–10.PubMedCrossRef
83.
Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5:19–33.PubMedCrossRef
84.
Ohhashi S, et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res. 2008;28:2205–12.PubMed
85.
Antonsson BE, Avramis VI, Nyce J, Holcenberg JS. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCK-1. Cancer Res. 1987;47:3672–8.PubMed
86.
Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol. 1989;24:203–10.PubMed
87.
Jordheim LP, Guittet O, Lepoivre M, Galmarini M, Dumontest C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther. 2005;4:1268–76.PubMedCrossRef
88.
Boukovinas I, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PloS ONE. 2008;3:e3695.PubMedCrossRef
89.
Rosell R, Danenberg KD, Alberola V. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10:1318–25.PubMedCrossRef
90.
Souglakos J, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 2008;98:1710–5.PubMedCrossRef
91.
Kwon WS, et al. Ribonucleotide reductase M1 (RRM 1) 2464 G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 2006;16:429–38.PubMedCrossRef
92.
Ando T, Nishimura M, Oka Y. Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia. 2000;14:1915–20.PubMedCrossRef
93.
Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest. 1974;53:287–90.CrossRef
94.
Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogs: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–90.PubMedCrossRef
95.
Yonemori K, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus visplatin. Clin Cancer Res. 2005;11:2620–4.PubMedCrossRef
96.
Gilbert JA, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12:1794–803.PubMedCrossRef
97.
Schirmer M, Stegmann AP, Geisen F, Konwalinka G. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Exp Hematol. 1998;26:1223–8.PubMed
98.
Sève P, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer. 2005;49:363–70.PubMedCrossRef
99.
Smid K, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25:1001–7.PubMedCrossRef
Metadata
Title
Pharmacogenetics and pharmacoepigenetics of gemcitabine
Authors
M. Candelaria
E. de la Cruz-Hernández
E. Pérez-Cárdenas
C. Trejo-Becerril
O. Gutiérrez-Hernández
A. Dueñas-González
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9349-y

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue

Original Paper

Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells

Original Paper

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

Original Paper

Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan

Original Paper

Clinicopathological analysis of primary epithelial appendiceal neoplasms

Original Paper

Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters

Original Paper

Retracted Article: Interleukin-1beta and tumor necrosis factor-alpha regulation of CDX2 homeobox gene through nuclear factor kappa B-dependent pathway in the intestinal-type gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits